Zepp Health (NYSE:ZEPP) Stock: Insider Pengtao Yu Sells 4,251 Shares

Key Points

• Insider Pengtao Yu sold 4,251 Zepp Health shares at an average price of $4.09, generating $17,386.59. Yu retained 98,491 shares after the transaction, a 4.14% reduction in ownership.
• Zepp Health shares opened at $4.12 after declining 2.7%; the stock has a market capitalization of approximately $60.55 million and trades near its 52-week low of $3.85.
• Analyst sentiment is mixed, with one Buy and one Sell rating producing a consensus “Hold” rating and a $53.01 target price. Institutional investors and hedge funds own 52.61% of the company.

Zepp Health Corporation Sponsored ADR (NYSE:ZEPP - Get Free Report) insider Pengtao Yu sold 4,251 shares of Zepp Health stock in a transaction dated Thursday, September 24th. The shares were sold at an average price of $4.09, for a total value of $17,386.59. Following the completion of the transaction, the insider directly owned 98,491 shares of the company's stock, valued at $402,828.19. This represents a 4.14% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Zepp Health Trading Down 2.7%

ZEPP opened at $4.12 on Friday. The company has a current ratio of 0.90, a quick ratio of 0.70 and a debt-to-equity ratio of 0.30. The stock has a market capitalization of $60.55 million, a PE ratio of -1.50 and a beta of 1.87. Zepp Health Corporation Sponsored ADR has a 1-year low of $3.85 and a 1-year high of $61.85. The firm has a 50-day moving average price of $4.88 and a two-hundred day moving average price of $8.51.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on ZEPP. Wall Street Zen cut shares of Zepp Health from a "hold" rating to a "sell" rating in a research report on Tuesday, September 8th. Fundamental Research set a $53.01 price objective on Zepp Health and gave the company a "buy" rating in a research report on Tuesday, August 11th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Zepp Health in a research note on Tuesday, September 8th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $53.01.

Institutional Trading of Zepp Health

A number of institutional investors have recently bought and sold shares of ZEPP. Monolith Management Ltd bought a new stake in Zepp Health in the fourth quarter valued at about $3,601,000. Harvest Fund Management Co. Ltd boosted its holdings in Zepp Health by 6.7% during the fourth quarter. Harvest Fund Management Co. Ltd now owns 44,800 shares of the company's stock worth $1,207,000 after buying an additional 2,800 shares during the last quarter. Engineers Gate Manager LP grew its position in shares of Zepp Health by 44.4% during the 2nd quarter. Engineers Gate Manager LP now owns 20,917 shares of the company's stock worth $109,000 after buying an additional 6,433 shares during the period. Finally, AXQ Capital LP acquired a new position in shares of Zepp Health during the 2nd quarter worth about $85,000. Institutional investors and hedge funds own 52.61% of the company's stock.

About Zepp Health

Zepp Health Corporation NYSE: ZEPP is a wearable technology company that develops smart health and fitness devices, along with digital platforms and services designed to help consumers monitor and improve their wellness. Its products collect and analyze information such as activity, sleep, heart rate and other health-related metrics.

The company's principal consumer brand is Amazfit, which offers smartwatches, fitness trackers and related accessories. Zepp Health also operates the Zepp brand of digital health software and services and has introduced products and services focused on areas such as sleep and hearing health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.